Navigation Links
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
Date:11/19/2007

AVALIDE demonstrated powerful mean blood pressure reductions of 30.8 mm Hg systolic blood pressure (SBP) and 24.0 mm Hg diastolic blood pressure (DBP) at five weeks and 21.1/19.3 mm Hg (SBP/DBP) for irbesartan alone in a study

of patients with severe hypertension AVALIDE also demonstrated mean BP reductions of 27.1/14.6 mm Hg (SBP/DBP) at 8 weeks, and 22.1/11.6 mm Hg and 15.7/7.3 mm Hg (SBP/DBP) reductions respectively for irbesartan and HCTZ alone, in a study of patients with

moderate hypertension

PARIS and PRINCETON, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Sanofi- aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for the antihypertensive agent AVALIDE for initial use in patients with hypertension who are likely to need multiple drugs to achieve their blood pressure goals.

The approval is based on data from two clinical trials involving more than 1,200 patients with moderate or severe high blood pressure.

In the first double-blind, active-controlled, seven-week trial, patients with severe hypertension (mean baseline 172/113 mm Hg SBP/DBP) were randomly treated with either AVALIDE 150/12.5 mg (n=468) or irbesartan 150 mg monotherapy (n=227). After one week, all doses were doubled. At five weeks, AVALIDE(R) (irbesartan-hydrochlorothiazide) 300/25 mg demonstrated mean blood pressure reductions of 30.8/24.0 mm Hg versus 21.1/19.3 mm Hg (SBP/DBP) for irbesartan 300 mg alone (P<.0001).

In the second double-blind, active-controlled, 12-week trial, patients with moderate hypertension (mean baseli
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... 2010 CareFusion (NYSE: ... today launched the EnVe™ ventilator , a ... 70-80 pounds lighter than other ventilators with similar ... The EnVe ventilator has the capability to ...
... Dec. 20, 2010 Codexis, Inc. (Nasdaq: CDXS ... Jaffray Clean Technology & Renewables Conference, to be held in ... be made by Robert Lawson, Senior Vice President and Chief ... noon Eastern Time.  A webcast and replay will be available ...
Cached Medicine Technology:CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 2CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 3
(Date:12/24/2014)... Dennis Thompson HealthDay ... There,s good news about the experimental Ebola vaccine that U.S. ... research shows a precursor of that vaccine produced a ... version of the vaccine, when given to more than 100 ... and white blood cells that could potentially protect a person ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Long-term fear of terrorists ... early death, a new study from Israel suggests. , , ... study involved 17,300 Israelis. In Israel, the threat of war ... than 60 years. "We wanted to test whether fear ... increased risk of death," study author Hermona Soreq, a professor ...
(Date:12/24/2014)... -- If you are a high-risk heart patient, you ... by a cardiologist, new research suggests. Survival rates ... for annual professional meetings, Harvard researchers report. Sixty ... to a teaching hospital during one of these meetings ... these meetings were not taking place. "That,s a ...
(Date:12/22/2014)... 2014 As early as thirty, gravity ... in the form of “jowls." The dreaded droopiness usually ... the marionette line or smile lines. Aging can be ... but as the deep facial tissues descend, jowls inevitably ... fillers that can be used under the skin to ...
(Date:12/22/2014)... Sagacious Consultants, the premier full-service Epic consulting ... their ad hoc report writing service to meet the ... up for an annual subscription and get a fixed ... deeply discounted hourly rate. , Customers can choose ... discounted rate. Subscription hours are contracted in 25 hour ...
Breaking Medicine News(10 mins):Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3
... Speaker Nancy Pelosi,delivered remarks this morning at the ... members of Congress, and hundreds of,children and seniors. ... full,funding of the State Children,s Health Insurance Program ... ask me what the three most important issues ...
... BETHESDA, Md., Sept. 6 Montana native and health ... Center Billings, MT, has been,installed to the post ... Health Centers (NACHC). Ceremonies took place at NACHC,s ... in Dallas, TX,which drew thousands of health center ...
... to make open-heart,surgery a minimally invasive procedure ... of Health Bioengineering Research Partnership award.,Professor Pierre ... surgeon Pedro del Nido, M.D., at Children,s ... Inc. (Van Nuys,CA) will collaborate to develop ...
... finds it brings the patient real benefit, too , ... partners with Alzheimer,s disease report better physical health if ... shows. , "Preserving the health of spouse caregivers through ... disease, as caregivers who are in poor health are ...
... 6 In response to,reports about the potential closure ... today reassured employees that the,civil section of the facility ... of closing the civil section of Warren,State Hospital and ... in,which residents and counties have come to depend," said ...
... on most common cause of inherited mental ... impairment and Parkinson-like syndrome, SAN FRANCISCO, ... California, Davis, School of Medicine and the M.I.N.D.,Institute, in collaboration ... Interdisciplinary Research Consortium grant from,the National Institutes of Heath, the ...
Cached Medicine News:Health News:Pelosi: SCHIP Bill a Giant Step for America's Children 2Health News:Montana Health Care Leader Elected Board Chair of National Association 2Health News:Minimally Invasive Heart Surgery Research Wins N.I.H. Award 2Health News:Counseling Boosts Alzheimer's Caregivers' Health 2Health News:PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors 2Health News:$21.8 Million NIH Grant for Fragile X Research 2Health News:$21.8 Million NIH Grant for Fragile X Research 3Health News:$21.8 Million NIH Grant for Fragile X Research 4
... The VacoSplint has a rigid shell with ... an immobilized foot/ankle. The VacoSplint is a non-weight ... weight bear he/she should transfer to the STORM ... remove the nylon liner from the STORM and ...
The Active Ankle Trainer model provides medial/lateral support and optimum ankle mobility for chronic and prophylactic use....
... Walker Pediatric Boot is the ... boot that offers superior comfort ... two sizes are offered thus ... will fit left or right, ...
... features a more open design of our ... Conformer boots. It is used to treat ... patients, plantar fasciitis, bone bruises (stone bruises), ... foot condition that might respond well to ...
Medicine Products: